Triptorelin SIF is a common palliative treatment for men with advanced or metastatic prostate cancer. It is also suitable for breast cancer, precocious puberty, estrogen-dependent diseases (such as endometriosis or uterine fibroids), and assisted reproduction or transgender. Triptorelin drug itself has proven to be safe and effective in clinical applications. FP-014 is a long-acting sustained release dosage form, which is administered every three months and every six months, which can reduce the number of injections and improve patient compliance. This product is a good complement to FP-001/FP-011.